EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades?

Ashot Avagimyan, Rosalinda Madonna, Mohammad Sheibani, Nana Pogosova, Artem Trofimenko, Olga Urazova, Laura Iop, Zinaida Jndoyan, Hasmik Yeranosyan, Anahit Aznauryan, Karmen Sahakyan, Anna Petrosyan und 12 weitere

Vascular Pharmacology · 2025-09 · 160 · 107526

DOI: 10.1016/j.vph.2025.107526 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025-09. Verfasst von Ashot Avagimyan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. Electronic address: ashot.avagimyan@meduni.am. Hauptthemen laut MEDLINE: Doxorubicin, Antibiotics, Antineoplastic, Translational Research, Biomedical, Heart Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 158 Literaturangaben. Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, European Commission, Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anthracyclines remain the cornerstone of treatment for malignancies with dose-dependent cardiac damage, ranging from oxidative stress and mitochondrial dysfunction to DNA damage and ferroptosis, and continue to compromise patient outcome. Animal models, encompassing rodents, rabbits, pigs, and nonhuman primates, are essential for investigating doxorubicin (DOX)-induced cardiovascular toxicity. Acute models facilitate rapid evaluation of cardiac injury; however, they frequently fail to replicate chronic human cardiomyopathy. In contrast, chronic models represent clinical scenarios more accurately but encounter logistical challenges. Species-specific variations in drug metabolism, cardiac physiology, and compensatory mechanisms further complicate the extrapolation. The primary limitations of existing models include the absence of comorbid conditions, lack of combination chemotherapy protocols, and underrepresentation of sex- and age-specific responses. Addressing these challenges is crucial for the development of effective and personalized cardioprotective strategies in cardio-oncology. This review explores the translational challenges of DOX-induced cardiotoxicity, a critical limitation in the development of new cardioprotective strategies in cardio-oncology despite decades of research. We will elucidate the underlying factors that contribute to the difficulties in translating experimental in vivo results into clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinAntibiotics, AntineoplasticTranslational Research, BiomedicalHeart DiseasesAnimalsHumansCardiotoxicityDisease Models, AnimalRisk AssessmentRisk Factors

Stichwörter der Autor:innen

Cardio-oncologyCardiomyopathyCardiotoxicityDoxorubicinModels

Substanzen

DoxorubicinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. Electronic address: ashot.avagimyan@meduni.am.
  • Cardiology Division, Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy. Electronic address: rosalinda.madonna@unipi.it.
  • Razi Drug Research Centre, Iran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Deputy of General Director for Sciences and Preventive Cardiology, National Medical Research of Cardiology after Acad. E. I. Chazov, Moscow, Russia; Head of Evidence-Based Medicine Department, Peoples' Friendship Univer…
  • Department of Pathophysiology, Kuban State Medical University, Krasnodar, Russia.
  • Head of Department of Pathophysiology, Siberian State Medical University, Tomsk, Russia.

Förderung

  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • European Commission
  • Ministero dell'Università e della Ricerca

Zitieren

APA

Avagimyan, A., Madonna, R., Sheibani, M., Pogosova, N., Trofimenko, A., Urazova, O., Iop, L., Jndoyan, Z., Yeranosyan, H., Aznauryan, A., Sahakyan, K., Petrosyan, A., Petrosyan, R., Tatoyan, M., Mkrtchyan, G., Sulemaniayants, E., Meltonyan, G., Kuzniatsou, A., Mukherjee, R., …, & Sarrafzadegan, N. (2025). Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades?. Vascular Pharmacology, 160, 107526. https://doi.org/10.1016/j.vph.2025.107526

Vancouver

Avagimyan A, Madonna R, Sheibani M, Pogosova N, Trofimenko A, Urazova O, et al. Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades?. Vascular Pharmacology. 2025;160:107526. doi:10.1016/j.vph.2025.107526

BibTeX
@article{Avagimyan2025,
  author = {Avagimyan, Ashot and Madonna, Rosalinda and Sheibani, Mohammad and Pogosova, Nana and Trofimenko, Artem and Urazova, Olga and Iop, Laura and Jndoyan, Zinaida and Yeranosyan, Hasmik and Aznauryan, Anahit and Sahakyan, Karmen and Petrosyan, Anna and Petrosyan, Ruzanna and Tatoyan, Marina and Mkrtchyan, Gayane and Sulemaniayants, Elina and Meltonyan, Goarik and Kuzniatsou, Aleh and Mukherjee, Rupak and Rezabakhsh, Aysa and Koliakos, George and Ottaviani, Giulia and Zoccai, Giuseppe-Biondi and Sarrafzadegan, Nizal},
  title = {Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades?},
  journal = {Vascular Pharmacology},
  year = {2025},
  volume = {160},
  pages = {107526},
  doi = {10.1016/j.vph.2025.107526}
}
Kostenlos starten →